-
1
-
-
77955635233
-
Cancer statistics 2010
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010
-
(2010)
CA Cancer J. Clin.
, vol.60
, Issue.5
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
73049112438
-
Worldwide variations in colorectal cancer
-
Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J. Clin. 59(6), 366-378 (2009
-
(2009)
CA Cancer J. Clin.
, vol.59
, Issue.6
, pp. 366-378
-
-
Center, M.M.1
Jemal, A.2
Smith, R.A.3
Ward, E.4
-
3
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
10.1002/ijc.25516 Epub ahead of print
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer DOI: 10.1002/ijc.25516 (2010) (Epub ahead of print
-
(2010)
Int. J. Cancer
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
4
-
-
33144482991
-
Current strategies in previously untreated advanced colorectal cancer
-
Williston Park 727
-
Penland SK, Goldberg RM. Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park) 18(6), 715-722, 727 (2004
-
(2004)
Oncology
, vol.18
, Issue.6
, pp. 715-722
-
-
Penland, S.K.1
Goldberg, R.M.2
-
5
-
-
21744436819
-
An overview of approaches to adjuvant therapy for colorectal cancer in the united states
-
Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin. Colorectal Cancer 5(Suppl. 1), S11-S18 (2005
-
(2005)
Clin. Colorectal Cancer
, vol.5
, Issue.1
-
-
Hobday, T.J.1
-
6
-
-
13744251436
-
Systemic therapy for colorectal cancer
-
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005
-
(2005)
N. Engl. J. Med.
, vol.352
, Issue.5
, pp. 476-487
-
-
Meyerhardt, J.A.1
Mayer, R.J.2
-
7
-
-
61349188341
-
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer MRC CR07 and NCIC-CTG C016: A multicentre randomised trial
-
Sebag-Montefiore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373(9666), 811-820 (2009
-
(2009)
Lancet
, vol.373
, Issue.9666
, pp. 811-820
-
-
Sebag-Montefiore, D.1
Stephens, R.J.2
Steele, R.3
-
8
-
-
34548557656
-
The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma
-
DOI 10.1097/01.sla.0000257358.56863.ce, PII 0000065820071100000001
-
Peeters KC, Marijnen CA, Nagtegaal ID et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246(5), 693-701 (2007 (Pubitemid 350035641)
-
(2007)
Annals of Surgery
, vol.246
, Issue.5
, pp. 693-701
-
-
Peeters, K.C.M.J.1
Marijnen, C.A.M.2
Nagtegaal, I.D.3
Kranenbarg, E.K.4
Putter, H.5
Wiggers, T.6
Rutten, H.7
Pahlman, L.8
Glimelius, B.9
Leer, J.W.10
Van De Velde, C.J.H.11
-
10
-
-
84960949820
-
Cancer: A biological approach III Viruses associated with neoplastic conditions IV practical applications
-
Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1(5023), 841-847 (1957
-
(1957)
Br. Med. J.
, vol.1
, Issue.5023
, pp. 841-847
-
-
Burnet, M.1
-
11
-
-
0028936599
-
Cancer risk after renal transplantation in the nordic countries 1964-1986
-
Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int. J. Cancer 60(2), 183-189 (1995
-
(1995)
Int. J. Cancer
, vol.60
, Issue.2
, pp. 183-189
-
-
Birkeland, S.A.1
Storm, H.H.2
Lamm, L.U.3
-
12
-
-
79151470865
-
Effects of chronic immunosuppression on long-term oncologic outcomes for colorectal cancer patients undergoing surgery
-
Khoury W, Lavery IC, Kiran RP. Effects of chronic immunosuppression on long-term oncologic outcomes for colorectal cancer patients undergoing surgery. Ann. Surg. 253(2), 323-327 (2010
-
(2010)
Ann. Surg.
, vol.253
, Issue.2
, pp. 323-327
-
-
Khoury, W.1
Lavery, I.C.2
Kiran, R.P.3
-
13
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
DOI 10.1126/science.1129139
-
Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006 (Pubitemid 44498003)
-
(2006)
Science
, vol.313
, Issue.5795
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pages, C.6
Tosolini, M.7
Camus, M.8
Berger, A.9
Wind, P.10
Zinzindohoue, F.11
Bruneval, P.12
Cugnenc, P.-H.13
Trajanoski, Z.14
Fridman, W.-H.15
Pages, F.16
-
14
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
-
(2010)
N. Engl. J. Med.
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
15
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
DOI 10.1200/JCO.2005.04.5252
-
Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006 (Pubitemid 46638945)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.19
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
Redfern, C.H.4
Nemunaitis, J.J.5
Valone, F.H.6
Verjee, S.S.7
Jones, L.A.8
Hershberg, R.M.9
-
16
-
-
78650801857
-
Sipuleucel-T: In metastatic castration-resistant prostate cancer
-
Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs 71(1), 101-108 (2011
-
(2011)
Drugs
, vol.71
, Issue.1
, pp. 101-108
-
-
Plosker, G.L.1
-
17
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
-
(2010)
N. Engl. J. Med.
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
18
-
-
0037174674
-
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
-
DOI 10.1126/science.1076514
-
Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002 (Pubitemid 35231542)
-
(2002)
Science
, vol.298
, Issue.5594
, pp. 850-854
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Robbins, P.F.3
Yang, J.C.4
Hwu, P.5
Schwartzentruber, D.J.6
Topalian, S.L.7
Sherry, R.8
Restifo, N.P.9
Hubicki, A.M.10
Robinson, M.R.11
Raffeld, M.12
Duray, P.13
Seipp, C.A.14
Rogers-Freezer, L.15
Morton, K.E.16
Mavroukakis, S.A.17
White, D.E.18
Rosenberg, S.A.19
-
19
-
-
55949125601
-
Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens
-
Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.32
, pp. 5233-5239
-
-
Dudley, M.E.1
Yang, J.C.2
Sherry, R.3
-
20
-
-
41149097574
-
Adoptive cell transfer: A clinical path to effective cancer immunotherapy
-
DOI 10.1038/nrc2355, PII NRC2355
-
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8(4), 299-308 (2008 (Pubitemid 351430867)
-
(2008)
Nature Reviews Cancer
, vol.8
, Issue.4
, pp. 299-308
-
-
Rosenberg, S.A.1
Restifo, N.P.2
Yang, J.C.3
Morgan, R.A.4
Dudley, M.E.5
-
21
-
-
70350772293
-
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
-
Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838-1847 (2009
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.19
, pp. 1838-1847
-
-
Kenter, G.G.1
Welters, M.J.2
Valentijn, A.R.3
-
22
-
-
33748987908
-
Cancer despite immunosurveillance: Immunoselection and immunosubversion
-
DOI 10.1038/nri1936, PII NRI1936
-
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6(10), 715-727 (2006 (Pubitemid 44453458)
-
(2006)
Nature Reviews Immunology
, vol.6
, Issue.10
, pp. 715-727
-
-
Zitvogel, L.1
Tesniere, A.2
Kroemer, G.3
-
23
-
-
78149488860
-
+ B cells: The other tumor-infiltrating lymphocytes
-
+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185(9), 4977-4982 (2010
-
(2010)
J. Immunol.
, vol.185
, Issue.9
, pp. 4977-4982
-
-
Nelson, B.H.1
-
24
-
-
40549140777
-
Therapeutic vaccines in cancer: Moving from immunomonitoring to immunoguiding
-
DOI 10.1586/14760584.7.1.1
-
van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev. Vaccines 7(1), 1-5 (2008 (Pubitemid 351357961)
-
(2008)
Expert Review of Vaccines
, vol.7
, Issue.1
, pp. 1-5
-
-
Van Der Burg, S.H.1
-
25
-
-
14844309609
-
Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits
-
DOI 10.1016/j.vaccine.2005.01.015
-
Uyl-de Groot CA, Vermorken JB, Hanna MG Jr et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23(17-18), 2379-2387 (2005 (Pubitemid 40341488)
-
(2005)
Vaccine
, vol.23
, Issue.17-18
, pp. 2379-2387
-
-
Uyl-de Groot, C.A.1
Vermorken, J.B.2
Hanna Jr., M.G.3
Verboom, P.4
Groot, M.T.5
Bonsel, G.J.6
Meijer, C.J.L.M.7
Pinedo, H.M.8
-
26
-
-
0033616482
-
Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
-
DOI 10.1016/S0140-6736(98)07186-4
-
Vermorken JB, Claessen AM, van TH et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150), 345-350 (1999 (Pubitemid 29088160)
-
(1999)
Lancet
, vol.353
, Issue.9150
, pp. 345-350
-
-
Vermorken, J.B.1
Claessen, A.M.E.2
Van Tinteren, H.3
Gall, H.E.4
Ezinga, R.5
Meijer, S.6
Scheper, R.J.7
Meijer, C.J.L.M.8
Bloemena, E.9
Ransom, J.H.10
Hanna Jr., M.G.11
Pinedo, H.M.12
-
27
-
-
18544386260
-
A Phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
-
Baars A, Claessen AM, Wagstaff J et al. A Phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br. J. Cancer 86(8), 1230-1234 (2002
-
(2002)
Br. J. Cancer
, vol.86
, Issue.8
, pp. 1230-1234
-
-
Baars, A.1
Claessen, A.M.2
Wagstaff, J.3
-
28
-
-
0033985949
-
Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283
-
Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148-157 (2000 (Pubitemid 30036348)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.1
, pp. 148-157
-
-
Harris, J.E.1
Ryan, L.2
Hoover Jr., H.C.3
Stuart, R.K.4
Oken, M.M.5
Benson III, A.B.6
Mansour, E.7
Haller, D.G.8
Manola, J.9
Hanna Jr., M.G.10
-
29
-
-
0027512782
-
Adjuvant active specific immunotherapy for human colorectal cancer: 6.5- Year median follow-up of a phase III prospectively randomized trial
-
Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390-399 (1993 (Pubitemid 23071033)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.3
, pp. 390-399
-
-
Hoover Jr., H.C.1
Brandhorst, J.S.2
Peters, L.C.3
Surdyke, M.G.4
Takeshita, Y.5
Madariaga, J.6
Muenz, L.R.7
Hanna Jr., M.G.8
-
30
-
-
54849420913
-
Efficiency of adjuvant active specific immunization with newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: Results of a prospective randomized trial
-
Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61-69 (2009
-
(2009)
Cancer Immunol. Immunother
, vol.58
, Issue.1
, pp. 61-69
-
-
Schulze, T.1
Kemmner, W.2
Weitz, J.3
Wernecke, K.D.4
Schirrmacher, V.5
Schlag, P.M.6
-
31
-
-
0037349751
-
Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet
-
Liang W, Wang H, Sun TM et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol. 9(3), 495-498 (2003 (Pubitemid 36372114)
-
(2003)
World Journal of Gastroenterology
, vol.9
, Issue.3
, pp. 495-498
-
-
Liang, W.1
Wang, H.2
Sun, T.-M.3
Yao, W.-Q.4
Chen, L.-L.5
Jin, Y.6
Li, C.-L.7
Meng, F.-J.8
-
32
-
-
8944263472
-
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma
-
Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2(1), 21-28 (1996 (Pubitemid 26042174)
-
(1996)
Clinical Cancer Research
, vol.2
, Issue.1
, pp. 21-28
-
-
Ockert, D.1
Schirrmacher, V.2
Beck, N.3
Stoelben, E.4
Ahlert, T.5
Flechtenmacher, J.6
Hagmuller, E.7
Buchcik, R.8
Nagel, M.9
Saeger, H.-D.10
-
33
-
-
10744233222
-
Vaccination with autologous tumor-derived heat-shock protein Gp96 after liver resection for metastatic colorectal cancer
-
Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9(9), 3235-3245 (2003 (Pubitemid 37082717)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.9
, pp. 3235-3245
-
-
Mazzaferro, V.1
Coppa, J.2
Carrabba, M.G.3
Rivoltini, L.4
Schiavo, M.5
Regalia, E.6
Mariani, L.7
Camerini, T.8
Marchiano, A.9
Andreola, S.10
Camerini, R.11
Corsi, M.12
Lewis, J.J.13
Srivastava, P.K.14
Parmiani, G.15
-
34
-
-
0032851163
-
Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A Phase I study
-
Sobol RE, Shawler DL, Carson C et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin. Cancer Res. 5(9), 2359-2365 (1999 (Pubitemid 29437314)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.9
, pp. 2359-2365
-
-
Sobol, R.E.1
Shawler, D.L.2
Carson, C.3
Van Beveren, C.4
Mercola, D.5
Fakhrai, H.6
Garrett, M.A.7
Barone, R.8
Goldfarb, P.9
Bartholomew, R.M.10
Brostoff, S.11
Carlo, D.J.12
Royston, I.13
Gold, D.P.14
-
35
-
-
77949423735
-
Regulating functional cell fates in CD8 T cells
-
Shrikant PA, Rao R, Li Q et al. Regulating functional cell fates in CD8 T cells. Immunol. Res. 46(1-3), 12-22 (2010
-
(2010)
Immunol. Res.
, vol.46
, Issue.1-3
, pp. 12-22
-
-
Shrikant, P.A.1
Rao, R.2
Li, Q.3
-
36
-
-
59249097938
-
Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine
-
Burgdorf SK, Fischer A, Myschetzky PS et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol. Rep. 20(6), 1305-1311 (2008
-
(2008)
Oncol. Rep.
, vol.20
, Issue.6
, pp. 1305-1311
-
-
Burgdorf, S.K.1
Fischer, A.2
Myschetzky, P.S.3
-
37
-
-
73349131696
-
Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients
-
Toh HC, Wang WW, Chia WK et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin. Cancer Res. 15(24), 7726-7736 (2009
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.24
, pp. 7726-7736
-
-
Toh, H.C.1
Wang, W.W.2
Chia, W.K.3
-
38
-
-
34248216550
-
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer
-
DOI 10.1007/s00262-006-0228-5
-
Alves PM, Levy N, Bouzourene H et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol. Immunother. 56(6), 839-847 (2007 (Pubitemid 46723576)
-
(2007)
Cancer Immunology, Immunotherapy
, vol.56
, Issue.6
, pp. 839-847
-
-
Alves, P.M.S.1
Levy, N.2
Bouzourene, H.3
Viatte, S.4
Bricard, G.5
Ayyoub, M.6
Vuilleumier, H.7
Givel, J.-C.R.8
Halkic, N.9
Speiser, D.E.10
Romero, P.11
Levy, F.12
-
39
-
-
6344284211
-
What types of colorectal cancer overexpress the MAGE protein?
-
Koketsu S, Watanabe T, Kazama S, Ishihara S, Komuro Y, Nagawa H. What types of colorectal cancer overexpress the MAGE protein? Hepatogastroenterology 51(60), 1648-1652 (2004 (Pubitemid 39389750)
-
(2004)
Hepato-Gastroenterology
, vol.51
, Issue.60
, pp. 1648-1652
-
-
Koketsu, S.-I.1
Watanabe, T.2
Kazama, S.3
Ishihara, S.4
Komuro, Y.5
Nagawa, H.6
-
40
-
-
0036690395
-
Expression of melanoma antigen-encoding genes MAGE by common primers for MAGE-A1 to -A6 in colorectal carcinomas among Koreans
-
Park MS, Park JW, Jeon CH, Lee KD, Chang HK. Expression of melanoma antigen-encoding genes (MAGE) by common primers for MAGE-A1 to -A6 in colorectal carcinomas among Koreans. J. Korean Med. Sci. 17(4), 497-501 (2002
-
(2002)
J. Korean Med. Sci.
, vol.17
, Issue.4
, pp. 497-501
-
-
Park, M.S.1
Park, J.W.2
Jeon, C.H.3
Lee, K.D.4
Chang, H.K.5
-
41
-
-
16344385247
-
Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue
-
DOI 10.1158/1078-0432.CCR-04-1365
-
Li M, Yuan YH, Han Y et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. 11(5), 1809-1814 (2005 (Pubitemid 40471843)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.5
, pp. 1809-1814
-
-
Li, M.1
Yuan, Y.-H.2
Han, Y.3
Liu, Y.-X.4
Yan, L.5
Wang, Y.6
Gu, J.7
-
42
-
-
11844265528
-
Part I: Vaccines for solid tumours
-
DOI 10.1016/S1470-2045(04)01610-9, PII S1470204504016109
-
Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol. 5(11), 681-689 (2004 (Pubitemid 40267853)
-
(2004)
Lancet Oncology
, vol.5
, Issue.11
, pp. 681-689
-
-
Mocellin, S.1
Mandruzzato, S.2
Bronte, V.3
Lise, M.4
Nitti, D.5
-
43
-
-
0037381134
-
Immunology and immunotherapy of colorectal cancer
-
DOI 10.1016/S1040-8428(02)00159-2
-
Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit. Rev. Oncol. Hematol. 46(1), 33-57 (2003 (Pubitemid 36369415)
-
(2003)
Critical Reviews in Oncology/Hematology
, vol.46
, Issue.1
, pp. 33-57
-
-
Dalerba, P.1
Maccalli, C.2
Casati, C.3
Castelli, C.4
Parmiani, G.5
-
44
-
-
33846935228
-
Unique human tumor antigens: Immunobiology and use in clinical trials
-
Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178(4), 1975-1979 (2007 (Pubitemid 46233392)
-
(2007)
Journal of Immunology
, vol.178
, Issue.4
, pp. 1975-1979
-
-
Parmiani, G.1
De Filippo, A.2
Novellino, L.3
Castelli, C.4
-
45
-
-
76149122520
-
5T4-modified vaccinia Ankara: Progress in tumor-associated antigen-based immunotherapy
-
Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther. 10(2), 281-287 (2010
-
(2010)
Expert Opin. Biol. Ther.
, vol.10
, Issue.2
, pp. 281-287
-
-
Amato, R.J.1
-
47
-
-
0343938862
-
The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire
-
Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164(2), 596-602 (2000 (Pubitemid 30043678)
-
(2000)
Journal of Immunology
, vol.164
, Issue.2
, pp. 596-602
-
-
Hernandez, J.1
Lee, P.P.2
Davis, M.M.3
Sherman, L.A.4
-
48
-
-
38849183472
-
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen
-
DOI 10.1158/0008-5472.CAN-07-3166
-
+ T-helper response against the p53 tumor antigen. Cancer Res. 68(3), 893-900 (2008 (Pubitemid 351206768)
-
(2008)
Cancer Research
, vol.68
, Issue.3
, pp. 893-900
-
-
Lauwen, M.M.1
Zwaveling, S.2
De Quartel, L.3
Ferreira Mota, S.C.4
Grashorn, J.A.C.5
Melief, C.J.M.6
Van Der Burg, S.H.7
Offringa, R.8
-
49
-
-
61349184597
-
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer
-
Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15(3), 1086-1095 (2009
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.3
, pp. 1086-1095
-
-
Speetjens, F.M.1
Kuppen, P.J.2
Welters, M.J.3
-
50
-
-
22244447452
-
Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire
-
DOI 10.1158/0008-5472.CAN-05-0666
-
+ T-cell repertoire. Cancer Res. 65(14), 6443-6449 (2005 (Pubitemid 40994433)
-
(2005)
Cancer Research
, vol.65
, Issue.14
, pp. 6443-6449
-
-
Bos, R.1
Van Duikeren, S.2
Van Hall, T.3
Kaaijk, P.4
Taubert, R.5
Kyewski, B.6
Klein, L.7
Melief, C.J.M.8
Offringa, R.9
-
51
-
-
27744573098
-
The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice
-
Gerloni M, Castiglioni P, Zanetti M. The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J. Immunol. 175(10), 6551-6559 (2005 (Pubitemid 41598897)
-
(2005)
Journal of Immunology
, vol.175
, Issue.10
, pp. 6551-6559
-
-
Gerloni, M.1
Castiglioni, P.2
Zanetti, M.3
-
52
-
-
33847412258
-
Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells
-
Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178(5), 2787-2793 (2007 (Pubitemid 46333156)
-
(2007)
Journal of Immunology
, vol.178
, Issue.5
, pp. 2787-2793
-
-
Turner, M.S.1
Cohen, P.A.2
Finn, O.J.3
-
53
-
-
53449093328
-
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1
-
Ding C, Wang L, Marroquin J, Yan J. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood 112(7), 2817-2825 (2008
-
(2008)
Blood
, vol.112
, Issue.7
, pp. 2817-2825
-
-
Ding, C.1
Wang, L.2
Marroquin, J.3
Yan, J.4
-
54
-
-
68149166302
-
Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice
-
Ryan SO, Vlad AM, Islam K, Gariepy J, Finn OJ. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol. Chem. 390(7), 611-618 (2009
-
(2009)
Biol. Chem.
, vol.390
, Issue.7
, pp. 611-618
-
-
Ryan, S.O.1
Vlad, A.M.2
Islam, K.3
Gariepy, J.4
Finn, O.J.5
-
55
-
-
0036812719
-
Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes
-
DOI 10.1034/j.1600-065X.2002.18816.x
-
Melief CJ, van der Burg SH, Toes RE, Ossendorp F, Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188, 177-182 (2002 (Pubitemid 35398875)
-
(2002)
Immunological Reviews
, vol.188
, pp. 177-182
-
-
Melief, C.J.M.1
Van Der Burg, S.H.2
Toes, R.E.M.3
Ossendorp, F.4
Offringa, R.5
-
56
-
-
42549138499
-
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
-
DOI 10.1038/nrc2373, PII NRC2373
-
Melief CJ, van der Burg SH. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8(5), 351-360 (2008 (Pubitemid 351589701)
-
(2008)
Nature Reviews Cancer
, vol.8
, Issue.5
, pp. 351-360
-
-
Melief, C.J.M.1
Van Der Burg, S.H.2
-
57
-
-
23844514389
-
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer
-
DOI 10.1158/1078-0432.CCR-05-0018
-
Weihrauch MR, Ansen S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 11(16), 5993-6001 (2005 (Pubitemid 41170331)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.16
, pp. 5993-6001
-
-
Weihrauch, M.R.1
Arisen, S.2
Jurkiewicz, E.3
Geisen, C.4
Xia, Z.5
Anderson, K.S.6
Gracien, E.7
Schmidt, M.8
Wittig, B.9
Diehl, V.10
Wolf, J.11
Bohlen, H.12
Nadler, L.M.13
-
58
-
-
33745758097
-
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer
-
DOI 10.1186/1479-5876-2-19
-
Tsuruma T. Hata F. Torigoe T. et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer J. Transl. Med. DOI: doi:10.1186/1479-5876-2-19 (2004) (Epub ahead of print (Pubitemid 39130353)
-
(2004)
Journal of Translational Medicine
, vol.2
, pp. 19
-
-
Tsuruma, T.1
Hata, F.2
Torigoe, T.3
Furuhata, T.4
Idenoue, S.5
Kurotaki, T.6
Yamamoto, M.7
Yagihashi, A.8
Ohmura, T.9
Yamaguchi, K.10
Katsuramaki, T.11
Yasoshima, T.12
Sasaki, K.13
Mizushima, Y.14
Minamida, H.15
Kimura, H.16
Akiyama, M.17
Hirohashi, Y.18
Asanuma, H.19
Tamura, Y.20
Shimozawa, K.21
Sato, N.22
Hirata, K.23
more..
-
59
-
-
0035679233
-
Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides
-
Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 7(12), 3950-3962 (2001 (Pubitemid 34044613)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.12
, pp. 3950-3962
-
-
Miyagi, Y.1
Imai, N.2
Sasatomi, T.3
Yamada, A.4
Mine, T.5
Katagiri, K.6
Nakagawa, M.7
Muto, A.8
Okouchi, S.9
Isomoto, H.10
Shirouzu, K.11
Yamana, H.12
Itoh, K.13
-
60
-
-
70349766001
-
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients
-
Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol. Immunother. 58(11), 1843-1852 (2009
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, Issue.11
, pp. 1843-1852
-
-
Hattori, T.1
Mine, T.2
Komatsu, N.3
-
61
-
-
34249879033
-
Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients
-
DOI 10.1111/j.1349-7006.2007.00498.x
-
Sato Y, Fujiwara T, Mine T et al. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci. 98(7), 1113-1119 (2007). (Pubitemid 46865399)
-
(2007)
Cancer Science
, vol.98
, Issue.7
, pp. 1113-1119
-
-
Sato, Y.1
Fujiwara, T.2
Mine, T.3
Shomura, H.4
Homma, S.5
Maeda, Y.6
Tokunaga, N.7
Ikeda, Y.8
Ishihara, Y.9
Yamada, A.10
Tanaka, N.11
Itoh, K.12
Harada, M.13
Todo, S.14
-
62
-
-
2342564465
-
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
-
DOI 10.1038/sj.bjc.6601711
-
Sato Y, Maeda Y, Shomura H et al. A Phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer 90(7), 1334-1342 (2004 (Pubitemid 38586257)
-
(2004)
British Journal of Cancer
, vol.90
, Issue.7
, pp. 1334-1342
-
-
Sato, Y.1
Maeda, Y.2
Shomura, H.3
Sasatomi, T.4
Takahashi, M.5
Une, Y.6
Kondo, M.7
Shinohara, T.8
Hida, N.9
Katagiri, K.10
Sato, K.11
Sato, M.12
Yamada, A.13
Yamana, H.14
Harada, M.15
Itoh, K.16
Todo, S.17
-
63
-
-
40549110815
-
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
-
DOI 10.1158/1078-0432.CCR-07-1880
-
+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14(1), 178-187 (2008 (Pubitemid 351377994)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.1
, pp. 178-187
-
-
Welters, M.J.P.1
Kenter, G.G.2
Piersma, S.J.3
Vloon, A.P.G.4
Lowik, M.J.G.5
Berends-Van Der Meer, D.M.A.6
Drijfhout, J.W.7
Valentijn, A.R.P.M.8
Wafelman, A.R.9
Oostendorp, J.10
Fleuren, G.J.11
Offringa, R.12
Melief, C.J.M.13
Van Der Burg, S.H.14
-
64
-
-
0035992254
-
Active specific immunotherapy with a β-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: Antibody response is associated with improved survival
-
Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a b-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. 8(7), 2044-2051 (2002 (Pubitemid 34753572)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.7
, pp. 2044-2051
-
-
Moulton, H.M.1
Yoshihara, P.H.2
Mason, D.H.3
Iversen, P.L.4
Triozzi, P.L.5
-
65
-
-
0030000007
-
A phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma
-
DOI 10.1006/jsre.1996.0264
-
Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63(1), 298-304 (1996 (Pubitemid 26197209)
-
(1996)
Journal of Surgical Research
, vol.63
, Issue.1
, pp. 298-304
-
-
Goydos, J.S.1
Elder, E.2
Whiteside, T.L.3
Finn, O.J.4
Lotze, M.T.5
-
66
-
-
0032975450
-
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
-
Khleif SN, Abrams SI, Hamilton JM et al. A Phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J. Immunother. 22(2), 155-165 (1999 (Pubitemid 29135900)
-
(1999)
Journal of Immunotherapy
, vol.22
, Issue.2
, pp. 155-165
-
-
Khleif, S.N.1
Abrams, S.I.2
Hamilton, J.M.3
Bergmann-Leitner, E.4
Chen, A.5
Bastian, A.6
Bernstein, S.7
Chung, Y.8
Allegra, C.J.9
Schlom, J.10
-
67
-
-
34748832351
-
Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides
-
DOI 10.1097/CJI.0b013e318133451c, PII 0000237120071000000009
-
Kavanagh B, Ko A, Venook A et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J. Immunother. 30(7), 762-772 (2007 (Pubitemid 47480759)
-
(2007)
Journal of Immunotherapy
, vol.30
, Issue.7
, pp. 762-772
-
-
Kavanagh, B.1
Ko, A.2
Venook, A.3
Margolin, K.4
Zeh, H.5
Lotze, M.6
Schillinger, B.7
Liu, W.8
Lu, Y.9
Mitsky, P.10
Schilling, M.11
Bercovici, N.12
Loudovaris, M.13
Guillermo, R.14
Lee, S.M.15
Bender, J.16
Mills, B.17
Fong, L.18
-
68
-
-
33646863192
-
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests
-
DOI 10.1093/annonc/mdl072
-
Lesterhuis WJ, de Vries IJ, Schuurhuis DH et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann. Oncol. 17(6), 974-980 (2006 (Pubitemid 43778989)
-
(2006)
Annals of Oncology
, vol.17
, Issue.6
, pp. 974-980
-
-
Lesterhuis, W.J.1
De Vries, I.J.M.2
Schuurhuis, D.H.3
Boullart, A.C.I.4
Jacobs, J.F.M.5
De Boer, A.J.6
Scharenborg, N.M.7
Brouwer, H.M.H.8
Van De Rakt, M.W.M.M.9
Figdor, C.G.10
Ruers, T.J.11
Adema, G.J.12
Punt, C.J.A.13
-
69
-
-
27944451397
-
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
-
DOI 10.1007/s00262-005-0021-x
-
Babatz J, Rollig C, Lobel B et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother. 55(3), 268-276 (2006 (Pubitemid 41682575)
-
(2006)
Cancer Immunology, Immunotherapy
, vol.55
, Issue.3
, pp. 268-276
-
-
Babatz, J.1
Rollig, C.2
Lobel, B.3
Folprecht, G.4
Haack, M.5
Gunther, H.6
Kohne, C.-H.7
Ehninger, G.8
Schmitz, M.9
Bornhauser, M.10
-
70
-
-
0035902607
-
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
-
DOI 10.1073/pnas.141226398
-
Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98(15), 8809-8814 (2001 (Pubitemid 32678109)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.15
, pp. 8809-8814
-
-
Fong, L.1
Hou, Y.2
Rivas, A.3
Benike, C.4
Yuen, A.5
Fisher, G.A.6
Davis, M.M.7
Engleman, E.G.8
-
71
-
-
0034880680
-
Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas
-
Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7(8), 2277-2284 (2001 (Pubitemid 32751625)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.8
, pp. 2277-2284
-
-
Sadanaga, N.1
Nagashima, H.2
Mashino, K.3
Tahara, K.4
Yamaguchi, H.5
Ohta, M.6
Fujie, T.7
Tanaka, F.8
Inoue, H.9
Takesako, K.10
Akiyoshi, T.11
Mori, M.12
-
72
-
-
20244383301
-
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules
-
DOI 10.1158/1078-0432.CCR-04-2172
-
Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11(8), 3017-3024 (2005 (Pubitemid 40525207)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.8
, pp. 3017-3024
-
-
Morse, M.A.1
Clay, T.M.2
Hobeika, A.C.3
Osada, T.4
Khan, S.5
Chui, S.6
Niedzwiecki, D.7
Panicali, D.8
Schlom, J.9
Lyerly, H.K.10
-
73
-
-
0041857805
-
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
-
DOI 10.1081/CNV-120018224
-
Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 21(3), 341-349 (2003 (Pubitemid 37055665)
-
(2003)
Cancer Investigation
, vol.21
, Issue.3
, pp. 341-349
-
-
Morse, M.A.1
Nair, S.K.2
Mosca, P.J.3
Hobeika, A.C.4
Clay, T.M.5
Deng, Y.6
Boczkowski, D.7
Proia, A.8
Neidzwiecki, D.9
Clavien, P.-A.10
Hurwitz, H.I.11
Schlom, J.12
Gilboa, E.13
Lyerly, H.K.14
-
74
-
-
51049083164
-
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
-
Kaufman HL, Lenz HJ, Marshall J et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin. Cancer Res. 14(15), 4843-4849 (2008
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.15
, pp. 4843-4849
-
-
Kaufman, H.L.1
Lenz, H.J.2
Marshall, J.3
-
75
-
-
0033766694
-
Phase I clinical trial of a recombinant canarypoxvirus ALVAC vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
-
Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49(9), 504-514 (2000
-
(2000)
Cancer Immunol. Immunother.
, vol.49
, Issue.9
, pp. 504-514
-
-
Horig, H.1
Lee, D.S.2
Conkright, W.3
-
76
-
-
0034122338
-
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 Transgenes in patients with recurrent CEA-expressing adenocarcinomas
-
von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6(6), 2219-2228 (2000 (Pubitemid 30399187)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.6
, pp. 2219-2228
-
-
Von Mehren, M.1
Arlen, P.2
Tsang, K.Y.3
Rogatko, A.4
Meropol, N.5
Cooper, H.S.6
Davey, M.7
McLaughlin, S.8
Schlom, J.9
Weiner, L.M.10
-
77
-
-
0033973608
-
Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
-
Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6(1), 24-33 (2000 (Pubitemid 30064972)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.1
, pp. 24-33
-
-
Zhu, M.1
Marshall, J.2
Cole, D.3
Schlom, J.4
Tsang, K.Y.5
-
78
-
-
0034551730
-
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
-
Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18(23), 3964-3973 (2000
-
(2000)
J. Clin. Oncol.
, vol.18
, Issue.23
, pp. 3964-3973
-
-
Marshall, J.L.1
Hoyer, R.J.2
Toomey, M.A.3
-
79
-
-
0032944458
-
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
-
Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17(1), 332-337 (1999 (Pubitemid 29022411)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.1
, pp. 332-337
-
-
Marshall, J.L.1
Hawkins, M.J.2
Tsang, K.Y.3
Richmond, E.4
Pedicano, J.E.5
Zhu, M.6
Schlom, J.7
-
80
-
-
0037966117
-
Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response
-
Ullenhag GJ, Frodin JE, Mosolits S et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin. Cancer Res. 9(7), 2447-2456 (2003 (Pubitemid 36849588)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.7
, pp. 2447-2456
-
-
Ullenhag, G.J.1
Frodin, J.-E.2
Mosolits, S.3
Kiaii, S.4
Hassan, M.5
Bonnet, M.C.6
Moingeon, P.7
Mellstedt, H.8
Rabbani, H.9
-
81
-
-
10744229393
-
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients
-
DOI 10.1038/sj.cgt.7700600
-
Menon AG, Kuppen PJ, van der Burg SH et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther. 10(7), 509-517 (2003 (Pubitemid 36842008)
-
(2003)
Cancer Gene Therapy
, vol.10
, Issue.7
, pp. 509-517
-
-
Menon, A.G.1
Kuppen, P.J.K.2
Van Der Burg, S.H.3
Offringa, R.4
Bonnet, M.C.5
Harinck, B.I.J.6
Tollenaar, R.A.E.M.7
Redeker, A.8
Putter, H.9
Moingeon, P.10
Morreau, H.11
Melief, C.J.M.12
Van De Velde, C.J.H.13
-
82
-
-
0036093592
-
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine
-
van der Burg SH, Menon AG, Redeker A et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8(5), 1019-1027 (2002 (Pubitemid 34517635)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.5
, pp. 1019-1027
-
-
Van Der Burg, S.H.1
Menon, A.G.2
Redeker, A.3
Bonnet, M.-C.4
Drijfhout, J.W.5
Tollenaar, R.A.E.M.6
Van De Velde, C.J.H.7
Moingeon, P.8
Kuppen, P.J.K.9
Offringa, R.10
Melief, C.J.M.11
-
83
-
-
33745223435
-
Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 TroVax induces immune responses which correlate with disease control: A Phase I/II trial
-
11 Pt 1
-
Harrop R, Connolly N, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin. Cancer Res. 12(11 Pt 1), 3416-3424 (2006
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 3416-3424
-
-
Harrop, R.1
Connolly, N.2
Redchenko, I.3
-
84
-
-
34547652648
-
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
-
DOI 10.1158/1078-0432.CCR-07-0704
-
Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 13(15 Pt 1), 4487-4494 (2007 (Pubitemid 47219718)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.15
, pp. 4487-4494
-
-
Harrop, R.1
Drury, N.2
Shingler, W.3
Chikoti, P.4
Redchenko, I.5
Carroll, M.W.6
Kingsman, S.M.7
Naylor, S.8
Melcher, A.9
Nicholls, J.10
Wassan, H.11
Habib, N.12
Anthoney, A.13
-
85
-
-
68549110430
-
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax MVA-5T4
-
Elkord E, Dangoor A, Burt DJ et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4Cancer Immunol. Immunother. 58(10), 1657-1667 (2009
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, Issue.10
, pp. 1657-1667
-
-
Elkord, E.1
Dangoor, A.2
Burt, D.J.3
-
86
-
-
67650136139
-
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases
-
Elkord E, Dangoor A, Drury NL et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J. Immunother. 31(9), 820-829 (2008
-
(2008)
J. Immunother.
, vol.31
, Issue.9
, pp. 820-829
-
-
Elkord, E.1
Dangoor, A.2
Drury, N.L.3
-
87
-
-
59449090966
-
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer
-
Zhang T, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol. Immunother. 58(4), 475-492 (2009
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, Issue.4
, pp. 475-492
-
-
Zhang, T.1
Herlyn, D.2
-
88
-
-
77954899030
-
Phase I study of single-agent anti-programmed death-1 MDX-1106 in refractory solid tumors: Safety clinical activity pharmacodynamics and immunologic correlates
-
Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.19
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
-
89
-
-
40549129230
-
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity
-
DOI 10.1158/1078-0432.CCR-07-1881
-
Kenter GG, Welters MJ, Valentijn AR et al. Phase I immunotherapeutic trial with long peptides spanning the e6 and e7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14(1), 169-177 (2008 (Pubitemid 351377993)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.1
, pp. 169-177
-
-
Kenter, G.G.1
Welters, M.J.P.2
Valentijn, A.R.P.M.3
Lowik, M.J.G.4
Berends-Van Der Meer, D.M.A.5
Vloon, A.P.G.6
Drijfhout, J.W.7
Wafelman, A.R.8
Oostendorp, J.9
Fleuren, G.J.10
Offringa, R.11
Van Der Burg, S.H.12
Melief, C.J.M.13
-
90
-
-
70249141312
-
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients a Phase II trial
-
Leffers N, Lambeck AJ, Gooden MJ et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a Phase II trial. Int. J. Cancer 125(9), 2104-2113 (2009
-
(2009)
Int. J. Cancer
, vol.125
, Issue.9
, pp. 2104-2113
-
-
Leffers, N.1
Lambeck, A.J.2
Gooden, M.J.3
-
91
-
-
0035113705
-
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
-
Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107(4), 477-484 (2001 (Pubitemid 32167994)
-
(2001)
Journal of Clinical Investigation
, vol.107
, Issue.4
, pp. 477-484
-
-
Knutson, K.L.1
Schiffman, K.2
Disis, M.L.3
-
92
-
-
0036605567
-
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
-
DOI 10.1200/JCO.2002.06.171
-
Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624-2632 (2002 (Pubitemid 34575634)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.11
, pp. 2624-2632
-
-
Disis, M.L.1
Gooley, T.A.2
Rinn, K.3
Davis, D.4
Piepkorn, M.5
Cheever, M.A.6
Knutson, K.L.7
Schiffman, K.8
-
93
-
-
22144439081
-
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
-
DOI 10.1007/s00262-004-0653-2
-
Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54(8), 721-728 (2005 (Pubitemid 40977140)
-
(2005)
Cancer Immunology, Immunotherapy
, vol.54
, Issue.8
, pp. 721-728
-
-
Knutson, K.L.1
Disis, M.L.2
-
94
-
-
18544373394
-
+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
-
DOI 10.1073/pnas.142417699
-
+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl Acad. Sci. USA 99(18), 11813-11818 (2002 (Pubitemid 34994481)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.18
, pp. 11813-11818
-
-
Gnjatic, S.1
Jager, E.2
Chen, W.3
Altorki, N.K.4
Matsuo, M.5
Lee, S.-Y.6
Chen, Q.7
Nagata, Y.8
Atanackovic, D.9
Chen, Y.-T.10
Ritter, G.11
Cebon, J.12
Knuth, A.13
Old, L.J.14
-
95
-
-
48149090897
-
Detection and functional analysis of tumor infiltrating T-lymphocytes TIL in liver metastases from colorectal cancer
-
Wagner P, Koch M, Nummer D et al. Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann. Surg. Oncol. 15(8), 2310-2317 (2008
-
(2008)
Ann. Surg. Oncol.
, vol.15
, Issue.8
, pp. 2310-2317
-
-
Wagner, P.1
Koch, M.2
Nummer, D.3
-
96
-
-
70449360735
-
Antigen-specific tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma
-
Bonertz A, Weitz J, Pietsch DH et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest 119(11), 3311-3321 (2009
-
(2009)
J. Clin. Invest
, vol.119
, Issue.11
, pp. 3311-3321
-
-
Bonertz, A.1
Weitz, J.2
Pietsch, D.H.3
-
97
-
-
25144476050
-
ABCE1 a member of ATP-binding cassette transporter gene encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients
-
Shichijo S, Ishihara Y, Azuma K et al. ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients. Oncol. Rep. 13(5), 907-913 (2005
-
(2005)
Oncol. Rep.
, vol.13
, Issue.5
, pp. 907-913
-
-
Shichijo, S.1
Ishihara, Y.2
Azuma, K.3
-
98
-
-
0035818515
-
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
-
DOI 10.1073/pnas.231326898
-
Saeterdal I, Bjorheim J, Lislerud K et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl Acad. Sci. USA 98(23), 13255-13260 (2001 (Pubitemid 33051349)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.23
, pp. 13255-13260
-
-
Saeterdal, I.1
Bjorheim, J.2
Lislerud, K.3
Gjertsen, M.K.4
Bukholm, I.K.5
Olsen, O.C.6
Nesland, J.M.7
Eriksen, J.A.8
Moller, M.9
Lindblom, A.10
Gaudernack, G.11
-
99
-
-
33745653128
-
Decoding hereditary colorectal cancer
-
DOI 10.1056/NEJMe068110
-
Boland CR. Decoding hereditary colorectal cancer. N. Engl. J. Med. 354(26), 2815-2817 (2006 (Pubitemid 43974200)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.26
, pp. 2815-2817
-
-
Boland, C.R.1
-
100
-
-
33748328364
-
Hereditary non-polyposis colerectal cancer: The rise and fall of a confusing term
-
Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J. Gastroenterol. 12(31), 4943-4950 (2006 (Pubitemid 44323261)
-
(2006)
World Journal of Gastroenterology
, vol.12
, Issue.31
, pp. 4943-4950
-
-
Jass, J.R.1
-
101
-
-
34250715384
-
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
-
DOI 10.1136/jmg.2007.048991
-
Vasen HF, Moslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancerJ. Med. Genet. 44(6), 353-362 (2007 (Pubitemid 46953715)
-
(2007)
Journal of Medical Genetics
, vol.44
, Issue.6
, pp. 353-362
-
-
Vasen, H.F.A.1
Moslein, G.2
Alonso, A.3
Bernstein, I.4
Bertario, L.5
Blanco, I.6
Burn, J.7
Capella, G.8
Engel, C.9
Frayling, I.10
Friedl, W.11
Hes, F.J.12
Hodgson, S.13
Mecklin, J.-P.14
Moller, P.15
Nagengast, F.16
Parc, Y.17
Renkonen-Sinisalo, L.18
Sampson, J.R.19
Stormorken, A.20
Wijnen, J.21
more..
-
102
-
-
0027285475
-
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
-
DOI 10.1038/363558a0
-
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429), 558-561 (1993 (Pubitemid 23186645)
-
(1993)
Nature
, vol.363
, Issue.6429
, pp. 558-561
-
-
Ionov, Y.1
Peinado, M.A.2
Malkhosyan, S.3
Shibata, D.4
Perucho, M.5
-
103
-
-
0027314411
-
Microsatellite instability in cancer of the proximal colon
-
Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260(5109), 816-819 (1993 (Pubitemid 23167612)
-
(1993)
Science
, vol.260
, Issue.5109
, pp. 816-819
-
-
Thibodeau, S.N.1
Bren, G.2
Schaid, D.3
-
104
-
-
0029112453
-
Microsatellite instability in ovarian neoplasms
-
King BL, Carcangiu ML, Carter D et al. Microsatellite instability in ovarian neoplasms. Br. J. Cancer 72(2), 376-382 (1995
-
(1995)
Br. J. Cancer
, vol.72
, Issue.2
, pp. 376-382
-
-
King, B.L.1
Carcangiu, M.L.2
Carter, D.3
-
105
-
-
0027366916
-
Genetic instability of microsatellites in endometrial carcinoma
-
Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 53(21), 5100-5103 (1993 (Pubitemid 23333372)
-
(1993)
Cancer Research
, vol.53
, Issue.21
, pp. 5100-5103
-
-
Risinger, J.I.1
Berchuck, A.2
Kohler, M.F.3
Watson, P.4
Lynch, H.T.5
Boyd, J.6
-
106
-
-
0029156945
-
Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract relation to clinicopathological data and family history
-
Keller G, Rotter M, Vogelsang H et al. Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history. Am. J. Pathol. 147(3), 593-600 (1995
-
(1995)
Am. J. Pathol.
, vol.147
, Issue.3
, pp. 593-600
-
-
Keller, G.1
Rotter, M.2
Vogelsang, H.3
-
107
-
-
0032542364
-
Genetic instabilities in human cancers
-
DOI 10.1038/25292
-
Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 396(6712), 643-649 (1998 (Pubitemid 29003936)
-
(1998)
Nature
, vol.396
, Issue.6712
, pp. 643-649
-
-
Lengauer, C.1
Kinzler, K.W.2
Vogelstein, B.3
-
108
-
-
0035171887
-
Different mechanisms in the tumorigenesis of proximal and distal colon cancers
-
DOI 10.1097/00001622-200101000-00013
-
Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr. Opin. Oncol. 13(1), 63-69 (2001 (Pubitemid 32060047)
-
(2001)
Current Opinion in Oncology
, vol.13
, Issue.1
, pp. 63-69
-
-
Lindblom, A.1
-
109
-
-
47049097894
-
Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer
-
DOI 10.1002/ijc.23570
-
Speetjens FM, Lauwen MM, Franken KL et al. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int. J. Cancer 123(4), 838-845 (2008 (Pubitemid 352032410)
-
(2008)
International Journal of Cancer
, vol.123
, Issue.4
, pp. 838-845
-
-
Speetjens, F.M.1
Lauwen, M.M.2
Franken, K.L.3
Janssen-Van Rhijn, C.M.4
Van Duikeren, S.5
Bres, S.A.6
Van De Velde, C.J.H.7
Melief, C.J.M.8
Kuppen, P.J.K.9
Van Der Burg, S.H.10
Morreau, H.11
Offringa, R.12
-
110
-
-
41349097776
-
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers
-
DOI 10.1053/j.gastro.2008.01.015, PII S0016508508000541
-
Schwitalle Y, Kloor M, Eiermann S et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134(4), 988-997 (2008 (Pubitemid 351459601)
-
(2008)
Gastroenterology
, vol.134
, Issue.4
, pp. 988-997
-
-
Schwitalle, Y.1
Kloor, M.2
Eiermann, S.3
Linnebacher, M.4
Kienle, P.5
Knaebel, H.P.6
Tariverdian, M.7
Benner, A.8
Von Knebel Doeberitz, M.9
-
111
-
-
48549099797
-
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers
-
Speetjens FM, Kuppen PJ, Morreau H, van der Burg SH. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 135(2), 711-712 (2008
-
(2008)
Gastroenterology
, vol.135
, Issue.2
, pp. 711-712
-
-
Speetjens, F.M.1
Kuppen, P.J.2
Morreau, H.3
Van Der Burg, S.H.4
-
112
-
-
63849224217
-
+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue
-
+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58(4), 520-529 (2009
-
(2009)
Gut.
, vol.58
, Issue.4
, pp. 520-529
-
-
Chaput, N.1
Louafi, S.2
Bardier, A.3
-
113
-
-
77955725489
-
Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients
-
Deng L, Zhang H, Luan Y et al. Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res. 16(16), 4105-4112 (2010
-
(2010)
Clin. Cancer Res.
, vol.16
, Issue.16
, pp. 4105-4112
-
-
Deng, L.1
Zhang, H.2
Luan, Y.3
-
114
-
-
77950468866
-
+ T/FOXP3 + cell ratio is a predictive marker for survival in patients with colorectal cancer
-
+ T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immunother. 59(5), 653-661 (2010
-
(2010)
Cancer Immunol. Immunother.
, vol.59
, Issue.5
, pp. 653-661
-
-
Suzuki, H.1
Chikazawa, N.2
Tasaka, T.3
-
115
-
-
33846913897
-
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance
-
Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178(4), 2155-2162 (2007 (Pubitemid 46233413)
-
(2007)
Journal of Immunology
, vol.178
, Issue.4
, pp. 2155-2162
-
-
Zhou, G.1
Levitsky, H.I.2
-
116
-
-
77955411096
-
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
-
USA
-
Welters MJ, Kenter GG, de Vos van Steenwijk PJ et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl Acad. Sci. USA 107(26), 11895-11899 (2010
-
(2010)
Proc. Natl. Acad. Sci.
, vol.107
, Issue.26
, pp. 11895-11899
-
-
Welters, M.J.1
Kenter, G.G.2
De Vos Van Steenwijk, P.J.3
-
117
-
-
43449101175
-
Tumor-specific regulatory T cells in cancer patients
-
Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum. Immunol. 69(4-5), 241-249 (2008
-
(2008)
Hum. Immunol.
, vol.69
, Issue.4-5
, pp. 241-249
-
-
Piersma, S.J.1
Welters, M.J.2
Van Der Burg, S.H.3
-
119
-
-
77958056009
-
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A Phase I/II study in metastatic melanoma patients
-
Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16(20), 5067-5078 (2010
-
(2010)
Clin. Cancer Res.
, vol.16
, Issue.20
, pp. 5067-5078
-
-
Jacobs, J.F.1
Punt, C.J.2
Lesterhuis, W.J.3
-
120
-
-
50949115267
-
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
-
Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112(3), 610-618 (2008
-
(2008)
Blood
, vol.112
, Issue.3
, pp. 610-618
-
-
Morse, M.A.1
Hobeika, A.C.2
Osada, T.3
-
121
-
-
0142090691
-
Magnitude and polarization of p53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors
-
DOI 10.1002/ijc.11419
-
van der Burg SH, Menon AG, Redeker A et al. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int. J. Cancer 107(3), 425-433 (2003 (Pubitemid 37266463)
-
(2003)
International Journal of Cancer
, vol.107
, Issue.3
, pp. 425-433
-
-
Van Der Burg, S.H.1
Menon, A.G.2
Redeker, A.3
Franken, K.L.M.C.4
Drijfhout, J.W.5
Tollenaar, R.A.E.M.6
Hartgrink, H.H.7
Van De Velde, C.J.H.8
Kuppen, P.J.K.9
Melief, C.J.M.10
Offringa, R.11
-
123
-
-
65549133014
-
Coordination of intratumoral immune reaction and human colorectal cancer recurrence
-
Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69(6), 2685-2693 (2009
-
(2009)
Cancer Res.
, vol.69
, Issue.6
, pp. 2685-2693
-
-
Camus, M.1
Tosolini, M.2
Mlecnik, B.3
-
126
-
-
42249100669
-
Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients
-
DOI 10.1158/1078-0432.CCR-07-4045
-
Speetjens FM, Kuppen PJ, Sandel MH et al. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin. Cancer Res. 14(8), 2276-2284 (2008 (Pubitemid 351551058)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.8
, pp. 2276-2284
-
-
Speetjens, F.M.1
Kuppen, P.J.K.2
Sandel, M.H.3
Menon, A.G.4
Burg, D.5
Van DeVelde, C.J.H.6
Tollenaar, R.A.E.M.7
De Bont, H.J.G.M.8
Nagelkerke, J.F.9
-
127
-
-
38049000452
-
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
-
Buckanovich RJ, Facciabene A, Kim S et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14(1), 28-36 (2008
-
(2008)
Nat. Med.
, vol.14
, Issue.1
, pp. 28-36
-
-
Buckanovich, R.J.1
Facciabene, A.2
Kim, S.3
-
128
-
-
0037298181
-
A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer
-
Menon AG, Fleuren GJ, Alphenaar EA et al. A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer. Cancer Immunol. Immunother. 52(2), 121-126 (2003 (Pubitemid 36337620)
-
(2003)
Cancer Immunology, Immunotherapy
, vol.52
, Issue.2
, pp. 121-126
-
-
Menon, A.G.1
Fleuren, G.J.2
Alphenaar, E.A.3
Jonges, L.E.4
Janssen Van Rhijn, C.M.5
Ensink, N.G.6
Putter, H.7
Tollenaar, R.A.E.M.8
Van De Velde, C.J.H.9
Kuppen, P.J.K.10
-
129
-
-
77949780426
-
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer
-
Mlecnik B, Tosolini M, Charoentong P et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138(4), 1429-1440 (2010
-
(2010)
Gastroenterology
, vol.138
, Issue.4
, pp. 1429-1440
-
-
Mlecnik, B.1
Tosolini, M.2
Charoentong, P.3
-
130
-
-
77957273591
-
Improved endpoints for cancer immunotherapy trials
-
Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388-1397 (2010
-
(2010)
J. Natl. Cancer Inst.
, vol.102
, Issue.18
, pp. 1388-1397
-
-
Hoos, A.1
Eggermont, A.M.2
Janetzki, S.3
-
131
-
-
37349020262
-
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
-
DOI 10.1007/s00262-007-0380-6
-
Janetzki S, Panageas KS, Ben-Porat L et al. Results and harmonization guidelines from two large-scale international ELISpot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVICancer Immunol. Immunother. 57(3), 303-315 (2008 (Pubitemid 350295382)
-
(2008)
Cancer Immunology, Immunotherapy
, vol.57
, Issue.3
, pp. 303-315
-
-
Janetzki, S.1
Panageas, K.S.2
Ben-Porat, L.3
Boyer, J.4
Britten, C.M.5
Clay, T.M.6
Kalos, M.7
Maecker, H.T.8
Romero, P.9
Yuan, J.10
Martin Kast, W.11
Hoos, A.12
-
132
-
-
37349077911
-
+ T lymphocytes by structural and functional assays
-
DOI 10.1007/s00262-007-0378-0
-
+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 57(3), 289-302 (2008 (Pubitemid 350295380)
-
(2008)
Cancer Immunology, Immunotherapy
, vol.57
, Issue.3
, pp. 289-302
-
-
Britten, C.M.1
Gouttefangeas, C.2
Welters, M.J.P.3
Pawelec, G.4
Koch, S.5
Ottensmeier, C.6
Mander, A.7
Walter, S.8
Paschen, A.9
Muller-Berghaus, J.10
Haas, I.11
Mackensen, A.12
Kollgaard, T.13
Thor Straten, P.14
Schmitt, M.15
Giannopoulos, K.16
Maier, R.17
Veelken, H.18
Bertinetti, C.19
Konur, A.20
Huber, C.21
Stevanovic, S.22
Wolfel, T.23
Van Der Burg, S.H.24
more..
-
133
-
-
68549133403
-
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the cancer vaccine consortium
-
Britten CM, Janetzki S, Ben-Porat L et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol. Immunother. 58(10), 1701-1713 (2009
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, Issue.10
, pp. 1701-1713
-
-
Britten, C.M.1
Janetzki, S.2
Ben-Porat, L.3
-
134
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
-
135
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised recist guideline version 1.1
-
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1Eur. J. Cancer 45(2), 228-247 (2009
-
(2009)
Eur. J. Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
136
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000 (Pubitemid 30099779)
-
(2000)
Journal of the National Cancer Institute
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
137
-
-
52649175424
-
New response criteria proposed for immunotherapies
-
Tuma RS. New response criteria proposed for immunotherapies. J. Natl Cancer Inst. 100(18), 1280-1281 (2008
-
(2008)
J. Natl. Cancer Inst.
, vol.100
, Issue.18
, pp. 1280-1281
-
-
Tuma, R.S.1
-
138
-
-
70350769383
-
Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination
-
Burgdorf SK, Claesson MH, Nielsen HJ, Rosenberg J. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol. 48(8), 1157-1164 (2009
-
(2009)
Acta Oncol.
, vol.48
, Issue.8
, pp. 1157-1164
-
-
Burgdorf, S.K.1
Claesson, M.H.2
Nielsen, H.J.3
Rosenberg, J.4
-
139
-
-
12944325331
-
A listing of human tumor antigens recognized by T cells: March 2004 update
-
DOI 10.1007/s00262-004-0560-6
-
Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54(3), 187-207 (2005). (Pubitemid 40174238)
-
(2005)
Cancer Immunology, Immunotherapy
, vol.54
, Issue.3
, pp. 187-207
-
-
Novellino, L.1
Castelli, C.2
Parmiani, G.3
|